Utility of protocol biopsy in renal recipients: Meta analysis and systematic review

苏日古嘎,吕军好,陈江华,吴建永
DOI: https://doi.org/10.3969/cndt.j.issn.1006-298X.2017.02.006
2017-01-01
Abstract:Objective:To evaluate the value of protocol biopsy in patients after renal transplantation.Methodology:Searches were applied to the following electronic database:Medline,Embase Database,and Cochrane Library.Randomized controlled trials evaluating the value of protocol biopsy for renal allograft recipients were included.Data were extracted independently by two reviewer.The risk of bias of included studies was assessed by the the Cochrane collaboration's tool for assessing risk of bias.Statistical analysis were performed with Ravman 5.0.Results:5 RCTs were included.Long term graft loss was significantly reduced (RR 0.43,95% CI 0.26 to 0.70,P< 0.001) by protocol biopsy after renal transplantation.Protocol biopsy may reduce the long term serum creatinine (WMD 38.21 μ mol/L,95% CI 54.83 to 21.60,P<0.001).For renal recipients whose basal immunosuppression was CNI (tacrolimus or cyclosporine).However,for those whose basal immunosuppression was tacrolimus,this effect was not notable.Conclusion:Treatment of subclinical changes detected by protocol biopsy could significantly improve the graft survival and might improve the allograft function.The incidence of main complication of protocol biopsy was rare.
What problem does this paper attempt to address?